For patients with limited-stage small cell lung cancer, adjuvant therapy with durvalumab leads to significantly longer ...

Adding perioperative durvalumab (Imfinzi) to neoadjuvant chemotherapy significantly improved survival outcomes in ...

BARCELONA — Adding the immune checkpoint inhibitor durvalumab to standard treatment for muscle-invasive bladder cancer (MIBC) ...

The FDA has approved AstraZeneca's Fasenra for eosinophilic granulomatosis with polyangiitis based on Phase 3 MANDARA trial ...

The HIMALAYA study showed that the combination of tremelimumab and durvalumab significantly improved overall survival in ...

While none of the experimental combinations met efficacy targets, durvalumab with monalizumab and ceralasertib showed ...

The recent ESMO 2024 data highlighted significant advancements in immunotherapy. Check out the results from Merck, BMY, ...

The lack of a disease-free survival benefit with adjuvant durvalumab in early-stage resected non-small cell lung cancer in ...

Adjuvant durvalumab failed to improve disease-free survival in resected EGFR- or ALK-negative non-small cell lung cancer.

Phase 2 results from the NeoCOAST-2 study have demonstrated that the combination of durvalumab with Dato-DXd yielded the ...

Incorporating perioperative durvalumab into treatment with neoadjuvant chemotherapy and radical cystectomy prolongs EFS and OS in patients with MIBC.

AstraZeneca Plc (AZN.L, AZN) announced that the NIAGARA Phase III trial showed its IMFINZI (durvalumab) in combination with ...